Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.

doi:10.3389/fimmu.2024.1401683

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.

Frontiers in immunology - 1 Jan 2024

Pavlovic Kristina, Carmona-Luque MDolores, Corsi Giulia I, Maldonado-Pérez Noelia, Molina-Estevez Francisco J, Peralbo-Santaella Esther, Cortijo-Gutiérrez Marina, Justicia-Lirio Pedro, Tristán-Manzano María, Ronco-Díaz Víctor, Ballesteros-Ribelles Antonio, Millán-López Alejandro, Heredia-Velázquez Paula, Fuster-García Carla, Cathomen Toni, Seemann Stefan E, Gorodkin Jan, Martin Francisco, Herrera Concha, Benabdellah Karim

Abstract excerpt

Introduction: Chimeric antigen receptor-expressing T cells (CAR T cells) have revolutionized cancer treatment, particularly in B cell malignancies. However, the use of autologous T cells for CAR T therapy presents several limitations, including high costs, variable efficacy, and adverse effects linked to cell phenotype. Methods: To overcome these challenges, we developed a strategy to generate universal and safe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Gene Editing

Share to Immunologic Memory

Share to Immunotherapy, Adoptive

Share to Receptors, Chimeric Antigen

Share to T-Lymphocytes

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 38868778
DOI: 10.3389/fimmu.2024.1401683
PMCID: PMC11167079

Genes

CD19
B2M

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.PMID 38868778Read ↗

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read ↗

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemiaSemantic proximity Read ↗

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapySemantic proximity Read ↗

Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic EffectsSemantic proximity Read ↗

Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regressionSemantic proximity Read ↗

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapySemantic proximity Read ↗

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapiesSemantic proximity Read ↗

Strengthening the CAR-T Cell Therapeutic Application using CRISPR/Cas9 TechnologySemantic proximity Read ↗

Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor EfficacySemantic proximity Read ↗

Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cellsSemantic proximity Read ↗

CRISPR–Cas9 applications in T cells and adoptive T cell therapiesSemantic proximity Read ↗

Rapid and efficient generation of antigen-specific isogenic T cells from cryopreserved blood samplesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.